GSK Analysts See 3.5% Turnover Growth Ahead of Q3 Results

GSK is due to report third-quarter results Wednesday with a 15-analyst consensus projecting higher turnover but lower core operating profit and core earnings per share than a year earlier. The consensus, effective Oct. 16, puts turnover at £8.842 billion, up about 3.5% from £8.547 billion in Q3 2025. The forecast includes £3.852 billion from specialty medicines, £2.624 billion from vaccines and £2.366 billion from general medicines. Analysts project core operating profit of £2.929 billion, down from £2.985 billion a year earlier, a decline of about 1.9%.

Source: TokenPost